The antibody efficiently inhibits the EGFR associated signal transduction, prevents proliferation, arrests the cell cycle in the G1 phase and decreases interleukin 6 (IL-6) secretion by the cancer cells (15, 16). The gene discussed is EGFR; the disease is cancer.